Amylin kept at neutral by Merrill

Amylin Pharmaceuticals Inc. was maintained by Merrill Lynch analyst Tom McGahren at a neutral rating after news from the American Diabetes Association meeting that Byetta's efficacy is holding up well three years out, oral DPP-IV inhibitors should enter the market in 2007 and the final phase 2 data for exenatide LAR and liraglutide (once-daily injectable) are comparable. Shares of the San Diego-based biopharmaceutical company were up 75 cents, or 1.67%, at $45.62 on volume of 3,344,540 shares versus the three-month running average of 2,533,290 shares. (Nasdaq: AMLN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.